The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2024
Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML
The combination of ivosidenib plus azacitidine significantly improved event-free survival compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE trial.
FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia
The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.
Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia
A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.
The Role of FLT3 Inhibitors for Treatment of AML
Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.
Approaches to Treatment of Ph+ ALL
A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).
Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.
Brentuximab Vedotin Plus Chemo Shows Strong Activity in Early-Stage Hodgkin Lymphoma
The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorable-risk, Hodgkin lymphoma.
Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies
July 23rd 2021Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.
Molecular Testing Turnaround Time and Treatment Delay
Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.
Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
July 22nd 2021An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.
Molecular Testing for Acute Myeloid Leukemia
Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.
FDA Grants Breakthrough Therapy Designation to Venetoclax/Azacitidine for MDS
The FDA has granted a breakthrough therapy designation to the combination of venetoclax plus azacitidine for use in the treatment of adult patients with previously untreated, intermediate-, high-, and very high–risk myelodysplastic syndromes based on the revised International Prognostic Scoring System.
Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML
July 21st 2021The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.
Relapsed/Refractory DLBCL: Sequencing Therapy
July 20th 2021Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.
Belumosudil Represents Promising Newly-Approved Option for Chronic GVHD
Belumosudil induced clinically meaningful, durable responses in patients with chronic graft-versus-host-disease, irrespective of previous treatment received, severity of disease, and number of organs involved.